Search

Displaying results 4381 - 4390 of 9322 in total
  1. Drug

    Amilomotide

    go.drugbank.com/drugs/DB05150
    Investigational

    It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients. … CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease.

  2. Drug

    AIT-034

    go.drugbank.com/drugs/DB06106
    Experimental

    not respond to Neotrofin. … AIT-034 does not induce the production of NGF, and its mechanism of action is therefore believed to be different than Neotrofin.

  3. Drug

    PR-15

    go.drugbank.com/drugs/DB06037
    Investigational

    PR-15 is a novel anti-platelet protein with the potential to treat arterial thrombosis occurring during acute coronary syndromes without the bleeding risk associated with existing agents.

  4. Drug

    Velusetrag

    go.drugbank.com/drugs/DB12702
    Investigational

    Velusetrag was discovered by Theravance through the application of its multivalent drug design in a research program dedicated to finding new treatments for GI motility disorders. … Velusetrag has been used in trials studying the treatment of Gastroparesis and Alzheimer's Disease.

  5. Drug

    5-androstenedione

    go.drugbank.com/drugs/DB01456
    ExperimentalIllicit

    In the United States, the Controlled Substance Act is inclusive to anabolic steroids and their precursors. … Apart from the positioning of a carbon-carbon double bond, its structure is similar to [4-androstenedione], which is a prohormone which is naturally produced in the body by the adrenal glands and gonads

  6. Drug

    Eliapixant

    go.drugbank.com/drugs/DB21465
    Investigational

    The usage of the INN stem '-pixant' in the name indicates that Eliapixant is a purinoreceptor (P2X) antagonist. … Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb).

  7. Drug

    CG7870

    go.drugbank.com/drugs/DB04981
    Investigational

    It is a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

  8. Drug

    Sunvozertinib

    go.drugbank.com/drugs/DB18925
    Investigational

    [A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor … [A40018] EGFR often have mutations that lead to unfavourable treatment options and prognosis.

  9. Drug

    ETC-588

    go.drugbank.com/drugs/DB05456
    Experimental

    LUV are capable of transporting excess cholesterol from the vasculature to the liver for eventual elimination as part of the reverse lipid transport (RLT) pathway. … It is believed that the removal of cholesterol by ETC-588 through this pathway may result in the reversal of atherosclerosis.

  10. Drug

    MB-07803

    go.drugbank.com/drugs/DB05053
    Investigational

    MB07803 is a second generation gluconeogenesis inhibitor for the treatment of type 2 diabetes. It is designed to block the metabolic pathway in the liver that is responsible for producing glucose.